Dorinano

Startup

DoriNano, a Harvard spinoff, is pioneering a new class of programmable nanoparticle delivery systems powered by DNA origami nanotechnology. The platform offers unmatched precision, customizability, stability, and targetability compared to conventional approaches such as LNPs and AAVs, enabling flexible multi-cargo loading, safe repeat dosing, and scalable manufacturing. The company is advancing both an internal oncology pipeline and strategic partnerships, including a clinical collaboration with Memorial Sloan Kettering Cancer Center for its lead immunotherapy against Head & Neck Carcinoma, DoriVac-101, and a sponsored research collaboration with Daiichi Sankyo (to be released).  Backed by peer-reviewed publications in Nature Nanotechnology and Nature Biomedical Engineering, angel and VC investments, promising NHP and rat non-GLP safety data, and operations at LabCentral with an expanded leadership team, DoriNano has raised $2.8 million pre-seed is raising a $10M seed round to drive DoriVac-101 into clinical development and generate two additional platform-derived drug candidates.

website